uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted February 17, 2018

FDA Warns Seller Reishi Mushroom Supplements

On February 7, 2018, the FDA issued a warning letter to Reishi D. International, Inc., following a facility inspection which found the company's Reishi D. supplement to be adulterated because it was prepared, packed, or held under conditions that violate Current Good Manufacturing Practices for dietary supplements. 

These violations include improper quality control, failure to collect samples of certain lots, and failure to establish and follow written procedures for fulfilling the requirements for returned dietary supplements.

Statements made to promote the product were found to be drug claims. For example, the brochure states "contains more than 30 different flavonoids and antioxidants to help control free radicals. Free radicals are caused by waste from our body cells that increase with...infections...and toxins."  

In addition, the company's Reishi D. product was found to be misbranded because the label provides incorrect serving size information and failed to provide other required information.

For more information about mushroom supplements, see's answer to the question Do reishi mushroom supplements boost the immune system, or have other benefits? >>

See related warnings: 

Seller of Prostate, Reishi Supplements Warned for Manufacturing Violations

Seller of Alpha Lipoic Acid, Cinnamon Supplements and More Warned For Manufacturing Violations

FDA Warns Seller of Menopause, Sexual Enhancement, Prostate Supplements and More For Manufacturing Violations

Seller of Prostate, Immune Supplements & More Warned for Manufacturing Violations

FDA Warns Seller of Probiotic and Omega-3 Supplements for Manufacturing Violations

To read the FDA's warning letter, use the link below.